Patient groups are spending millions of dollars on television and local advertisements targeting U.S. Sunday morning political talk shows.
An advertisement aimed at loosening proposed restrictions on new Alzheimer's treatments is seen in this undated handout image. UsAgainstAlzheimer?s Action/Handout via REUTERSMarch 13 - Patient groups are mounting a public pressure campaign aimed at persuading the U.S. government to loosen proposed restrictions on new Alzheimer's treatments, spending millions of dollars on television and local advertisements that began running during the Sunday morning political shows.
The highly restrictive move came after Aduhelm was approved by the Food and Drug Administration last June, even though only one of two late-stage trials showed that it helped slow cognitive decline. As written, the Medicare plan would also apply to plaque-clearing drugs in advanced development by Eli Lilly and CoUSAgainstAlzheimer's, one of the largest U.S.-based groups representing patients with the disease, said it is funding ads in the Washington D.C.
He said the group is spending millions on the campaign, which will feature Alzheimer's patients, including social media outreach and print ads on bus stops and other transportation in the Washington area. Many have the tag line "Alzheimer's patients can't wait." Aduhelm's price - cut in December to $28,200 from $56,000 per year - sparked concerns about Medicare's budget since Alzheimer's is an age-related disease and around 85% of people eligible for the drug are covered by the government plan.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Animal Shelters Warn of A Looming Crisis and Call on Americans to HelpAs we enter the third year of the coronavirus pandemic, a 'perfect storm of factors' has put pressure on understaffed U.S. shelters.
Read more »
Russia one of three countries to not have U.S. most favored nation statusTaking away the 'most favored nation' status is the latest move from the U.S. to try to pressure Russian President Vladimir Putin to end his assault on Ukraine.
Read more »
U.S. FDA approves AstraZeneca-Merck's Lynparza to treat early-stage breast cancerBritish drugmaker AstraZeneca Plc said the U.S. Food and Drug Administration approved its cancer drug, jointly developed with U.S.-based Merck & Co , as a treatment for patients with early-stage breast cancer with certain mutations.
Read more »
Could drugs prevent Alzheimer’s? These trials aim to find outResearchers are giving drugs to healthy people in hope of clearing away toxic proteins in the brain and warding off neurodegeneration.
Read more »
US Pays $2M a Month to Protect Mike Pompeo, Aide From Iran Threatthe cost of protecting Pompeo and former Iran envoy Brian Hook between August 2021 and February 2022 amounted to $13.1 million
Read more »
FDA issues warning over Philips breathing machine recallTwo Philips Respironics ventilators, continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP) machines had been recalled over concerns that a foam component could be dangerous.
Read more »